Septerna, Inc. (NASDAQ:SEPN – Get Free Report) CFO Gil Labrucherie sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $41.62, for a total value of $832,400.00. Following the transaction, the chief financial officer directly owned 20,000 shares of the company’s stock, valued at $832,400. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Septerna Trading Down 1.4%
Shares of SEPN stock traded down $0.57 during trading hours on Wednesday, reaching $39.45. The company’s stock had a trading volume of 298,919 shares, compared to its average volume of 418,598. Septerna, Inc. has a one year low of $21.63 and a one year high of $53.34. The stock has a market capitalization of $1.88 billion, a P/E ratio of -30.58 and a beta of 2.20. The firm’s fifty day simple moving average is $40.64 and its 200 day simple moving average is $33.37.
Septerna (NASDAQ:SEPN – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The business had revenue of $18.88 million for the quarter, compared to the consensus estimate of $20.78 million. As a group, equities research analysts forecast that Septerna, Inc. will post -1.51 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have commented on SEPN. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. JPMorgan Chase & Co. boosted their price target on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday, August 19th. Wells Fargo & Company increased their price target on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Raymond James Financial restated a “strong-buy” rating and issued a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. Finally, JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.44.
Check Out Our Latest Report on Septerna
Institutional Trading of Septerna
Hedge funds have recently modified their holdings of the business. Algert Global LLC increased its stake in shares of Septerna by 13.5% in the 3rd quarter. Algert Global LLC now owns 451,116 shares of the company’s stock worth $17,652,000 after acquiring an additional 53,629 shares in the last quarter. Soleus Capital Management L.P. lifted its position in Septerna by 20.0% during the 3rd quarter. Soleus Capital Management L.P. now owns 330,000 shares of the company’s stock valued at $12,913,000 after acquiring an additional 55,000 shares during the period. Checkpoint Capital L.P. bought a new stake in Septerna during the third quarter worth about $2,504,000. State Board of Administration of Florida Retirement System bought a new stake in Septerna during the third quarter worth about $232,000. Finally, First Trust Advisors LP grew its holdings in Septerna by 129.4% in the third quarter. First Trust Advisors LP now owns 17,750 shares of the company’s stock worth $695,000 after purchasing an additional 10,011 shares during the period.
About Septerna
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Read More
- Five stocks we like better than Septerna
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
